After joining the UdG in 1992 my activity was focused on research on bioactive peptides, building together a research group (LIPPSO: Laboratori d'Innovació en Processos i Productes de Síntesi Orgànica, recognized as a Consolidated research group by the Generalitat de Catalunya) and establishing since 2001 a strategic alliance with the CIDSAV group to focus the projects (MINECO) in the applied field of new antimicrobials. The ramifications of the research have led to the detection of anticancer, analgesic and neuroprotectives, anticoagulants, ACE and ACE2 inhibitors, etc. All of this reflected in the various projects and publications (+50 publications and 8 patents). At the European level I have participated in a Trilateral Project of the PLANT-KBBE Program (obtaining antimicrobial peptides to be expressed in rice plants as a biofactory); in collaboration with the U. de Lisboa the project U. E. PEOPLE. IAPP. PEP2BRAIN "Selected peptides as drug candidates directed to pain and neurodegeneration"; currently in H2020, PreHLB "Preventing HLB epidemics for ensuring citrus survival in Europe". In the field of collaborations with companies, it is worth highlighting the development of new anticoagulants in the INNPACTO-MICINN project (Investigation of inhibitors of complex formation prothrombinase and its use as anticoagulants), as well as various collaboration contracts (Medichem, Croda, Menadione, etc.). In the field of technology transfer, I have promoted and participate in the management of the spin-off company AMPbiotech, focused on to value and license antimicrobial technologies arising from basic research at the UdG.